Related Experiment Video
Updated: Jul 15, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
[Radiotherapy for prostate cancer]
1Institut für Radioonkologie, Wilhelminenspital der Stadt Wien, Wien, Osterreich. christian.stanek@wienkav.at
Wiener Medizinische Wochenschrift (1946)
|May 12, 2007
Summary
Prostate cancer treatment varies by stage. For low-risk cases, radiotherapy and surgery yield similar results. Higher doses and androgen ablation benefit high-risk patients, but optimal radiotherapy volumes and androgen deprivation strategies need refinement.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Context:
- Prostate cancer treatment selection depends on tumor stage and patient risk factors.
- Established treatments include Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, and Androgen Ablation, often used in combination.
- Current therapeutic approaches require refinement for optimal patient outcomes.
Purpose:
- To review current prostate cancer treatment modalities based on risk stratification.
- To identify areas for improvement in radiotherapy and androgen deprivation therapy for intermediate and high-risk prostate cancer.
- To highlight the need for standardized definitions and improved patient selection in radiotherapy.
Summary:
- Radical Prostatectomy and radiotherapy show comparable outcomes for low-risk, localized prostate cancer.
- Intermediate and high-risk prostate cancer patients may benefit from escalated radiotherapy doses and combined androgen ablation.
- Uncertainties persist regarding optimal radiotherapy target volumes and androgen deprivation timing/duration.
Impact:
- Standardized target volume definitions and dose prescriptions are needed for radiotherapy planning.
- Improved patient selection criteria for radiotherapy can enhance treatment efficacy.
- Further research is required to optimize androgen deprivation strategies in combination therapies.
